These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20405046)

  • 1. Evaluating the efficacy of a malaria vaccine.
    Small DS; Cheng J; Ten Have TR
    Int J Biostat; 2010 Feb; 6(2):Article 4. PubMed ID: 20405046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
    D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
    Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical case definitions and malaria vaccine efficacy.
    Rogers WO; Atuguba F; Oduro AR; Hodgson A; Koram KA
    J Infect Dis; 2006 Feb; 193(3):467-73. PubMed ID: 16388497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania.
    Alonso PL; Smith T; Schellenberg JR; Masanja H; Mwankusye S; Urassa H; Bastos de Azevedo I; Chongela J; Kobero S; Menendez C
    Lancet; 1994 Oct; 344(8931):1175-81. PubMed ID: 7934537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines.
    Penny MA; Maire N; Studer A; Schapira A; Smith TA
    PLoS One; 2008 Sep; 3(9):e3193. PubMed ID: 18784833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measures of clinical malaria in field trials of interventions against Plasmodium falciparum.
    Smith TA
    Malar J; 2007 May; 6():53. PubMed ID: 17475000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human challenge models: tools to accelerate the development of malaria vaccines.
    Cooper MM; Loiseau C; McCarthy JS; Doolan DL
    Expert Rev Vaccines; 2019 Mar; 18(3):241-251. PubMed ID: 30732492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress with new malaria vaccines.
    Webster D; Hill AV
    Bull World Health Organ; 2003; 81(12):902-9. PubMed ID: 14997243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
    Mahmoudi S; Keshavarz H
    Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malaria attributable fractions with changing transmission intensity: Bayesian latent class vs logistic models.
    Mwai K; Nkumama I; Thairu A; Mburu J; Odera D; Kimathi R; Nyamako L; Tuju J; Kinyanjui S; Musenge E; Osier F
    Malar J; 2022 Nov; 21(1):326. PubMed ID: 36369045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluating malaria attributable morbidity in endemic areas].
    Rogier C; Fusaï T; Pradines B; Trape JF
    Rev Epidemiol Sante Publique; 2005 Jun; 53(3):299-309. PubMed ID: 16227917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The first malaria vaccine: a significant milestone].
    Sauerwein RW
    Ned Tijdschr Geneeskd; 2015; 159():A9730. PubMed ID: 26732220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study.
    Camponovo F; Ockenhouse CF; Lee C; Penny MA
    BMC Infect Dis; 2019 Oct; 19(1):920. PubMed ID: 31664924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
    Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
    Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
    Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
    Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2000; (2):CD000129. PubMed ID: 10796492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group.
    Nosten F; Luxemburger C; Kyle DE; Ballou WR; Wittes J; Wah E; Chongsuphajaisiddhi T; Gordon DM; White NJ; Sadoff JC; Heppner DG
    Lancet; 1996 Sep; 348(9029):701-7. PubMed ID: 8806288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania.
    Tediosi F; Hutton G; Maire N; Smith TA; Ross A; Tanner M
    Am J Trop Med Hyg; 2006 Aug; 75(2 Suppl):131-43. PubMed ID: 16931824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.